Needham Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $41
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. ACAD | 0.00 |
Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:
ACAD) with a Buy and raises the price target from $38 to $41.